---
title: 'Features of immunometabolic depression as predictors of antidepressant treatment
  outcomes: pooled analysis of four clinical trials'
date: '2023-12-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38130122/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231222170724&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Depressive symptoms of people with more IMD features improved
  less when treated with antidepressants. However, clinical relevance is limited owing
  to small effect sizes in inconsistent associations. Whether these patients would
  benefit more from treatments targeting immunometabolic pathways remains to be ...'
disable_comments: true
---
CONCLUSIONS: Depressive symptoms of people with more IMD features improved less when treated with antidepressants. However, clinical relevance is limited owing to small effect sizes in inconsistent associations. Whether these patients would benefit more from treatments targeting immunometabolic pathways remains to be ...